Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 151

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 151
---
-Serono
Group in Switzerland and Israel between 1988 and 2000. Mr. Cohen-Arazi received a M.Sc. degree from the Hebrew University of Jerusalem,
Israel.

<div align='center'>91</div>

Mr. Pini Ben-Elazar, Director Nominee

Mr. Ben-Elazar will become
our director at the effective time of the registration statement to which this prospectus relates, and will serve as an External Director
under the Companies Law for a 3-year term. Mr. ben-Elazar is a very experienced executive as a Chief Executive Officer and as a director
with over 25 years of successful experience in the healthcare industry. He is a change and growth leader providing fiscal, strategic and
operations leadership in uniquely challenging situations, and is a professional negotiator harnessing effective and creative thinking
and communicating skills. Mr Ben-Elazar currently serves as the Chief Executive Officer of Mor Research Applications, Tech Transfer Office
of Clalit Health Services in Israel since 2003. He is also a director in numerous healthcare companies among them: Ceretrieve, Enox, DreamMed
Diabetes, Data2Life, NGS, APX ophthalmology, Zebra Medical Vision, and Galil Ofek. Mr. Ben-Elazar holds an MBA from Johnson & Wales
University, Providence, RI since 1996, a B.Sc in Hospitality Management, Johnson & Wales University, Providence, RI, and completed
the studies of the 8400 Health Network Leadership Program, Harvard Business School, in 2019.

Dr. Susan Alpert, Director Nominee

Dr. Susan Alpert will become
our director at the effective time of the registration statement to which this prospectus relates, and will serve as an External Director
under the Companies Law for a 3-year term. Dr. Alpert is currently the principle of SFADC LLC (aka SFA Regulatory, LLC) since 2019, a
one-person firm focused on the strategies needed to place medical devices and other medical products into the global market. She was a
Corporate Senior Vice President for Global Regulatory at Medtronic, Inc. and prior to that VP Regulatory Science at C.R. Bard, Inc. She
previously worked at the U.S. FDA where she held a variety of management positions in the centers dealing with drugs, devices and radiological
health, and foods. She was Director of the Office of Device Evaluation from 1993-1999.